Skip to content

Time RestrIcted Feeding For Improving Diabetes Risk (TRIFFID)

The Metabolic Impacts of Time-restricted Feeding in Men at High Risk of Type 2 Diabetes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03590158
Acronym
TRIFFID
Enrollment
15
Registered
2018-07-18
Start date
2018-07-17
Completion date
2019-06-29
Last updated
2019-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 Diabetes, Obesity

Brief summary

This study will explore the effects of eight weeks of time-restricted feeding (TRF) on body weight and composition, glycaemic control, 24-hour glucose profiles, glucoregulatory hormones, and cardiovascular risk in men at high risk of type 2 diabetes. The investigators hypothesise that 8 weeks of TRF will reduce body weight, improve body composition, improve glycaemic control and blood lipid profiles. The potential mechanism will be explored in terms of the changes in gene expression patterns and multi-omics level (e.g., adipose tissue transcriptome, blood proteome).

Detailed description

Following a 2 week baseline monitoring phase (food intake by smartphone APP, activity by accelerometer, glucose by continuous glucose monitor), participants will attend the metabolic clinic for testing (visit 0). Body weight, body composition (by DEXA), and blood pressure will be assessed. Blood and adipose tissue samples will be collected over 24-hour period for assessment of glucose, insulin, glucoregulatory hormones, blood lipids and adipose tissue transcriptome. Glucose and insulin responses to a standardised breakfast will be measured. All food will be provided for 3 days prior to the metabolic visit. Following visit 0, participants will be instructed to eat only within a 10-hour time frame each day for 8 weeks. Participants may self-select the precise window that best suits their lifestyles, however any food and drink must be consumed at least 3 hours prior to their usual bedtime. 24-hour glucose profiles, activity and food intake will be measured again at week 6-8. At the end of the 8 weeks, participants will return for a follow-up metabolic visit, identical to that at visit 0, except foods are provided with the 10h time frame.

Interventions

BEHAVIORALTRF

Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.

Sponsors

University of South Australia
CollaboratorOTHER
Salk Institute for Biological Studies
CollaboratorOTHER
University of Adelaide
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
40 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Waist circumference ≥94 cm * Weight-stable (\< 5 % fluctuation in their body weight for past 6-months at study entry)

Exclusion criteria

* Personal history and/or diagnosis of: diabetes, cancer, major psychiatric disorders, liver disease, gastro-intestinal surgery or disease (including malabsorption), eating disorders, anaemia, insomnia, cardiovascular disease deemed unstable by the study physician. * use of prescribed or non-prescribed medications which may affect energy metabolism, gastrointestinal function, body weight or appetite, sleep (e.g: domperidone and cisapride, anticholinergic drugs (e.g.: atropine), metoclopramide, orlistat, thyroid medications, diuretics, glucocorticoids, sex steroids, metformin, dipeptidyl peptidase-IV inhibitors, melatonin) * recent weight change in past 3 months (\> 5% current body weight) * individuals who regularly perform high intensity exercise (\>2 week) * current intake of \> 140g alcohol/week * current smokers of cigarettes/cigars/marijuana/e-cigarettes/vaporisers * current intake of any illicit substance * unable to comprehend study protocol * currently performing shift work * has undertaken, or is planning to undertake, trans meridian travel during the study period, or the preceding 60 days * do not own a smartphone * eats for less than a 12-hour period per day

Design outcomes

Primary

MeasureTime frameDescription
Glycaemia2.5 hoursChange in postprandial glucose (iAUC) following a standard breakfast

Secondary

MeasureTime frameDescription
Blood lipids8 weekschanges in blood lipid profile (total cholesterol, HDL-, LDL- cholesterol and triglycerides)
Physical activity and sleep8 weeksAn ancillary study will measure the changes in sleep and physical activity monitored by a wrist actigraph for 14 days.
Food intake and meal timing8 weeksAn ancillary study will measure the changes in food intake and meal timing as recorded via a photography based smartphone App over 2 weeks. The analysis of the App data including but not limited to eating duration at baseline, changes in eating duration after intervention, calorie distribution throughout the day, meal frequency, meal intervals, and macronutrients intake.
Continuous glucose monitoring8 weeksAn ancillary study will measure the changes in glucose level by CGM for 14 days. Daily glucose patterns including free habitual diet, 3-day lead-in food will be measured separately. The analysis of the CGM data including but not limited to assess the mean amplitude of glycaemic excursions (MAGE), continuous overall net glycaemic action (CONGA), mean glucose concentrations.
Objective sleep8 weeksChanges in objective sleep status measured by laboratory polysomnography (PSG).
Insulin2.5 hoursChange in fasting and postprandial insulin following a standard breakfast.
HbA1c8 weeksChange in HbA1c
Body weight8 weeksChange in body weight
Body composition8 weeksChange in body fat mass and fat free mass
Waist and hip circumference8 weeksChange in waist and hip circumference
24-hour glucose profile8 weeksChange in 24-hour glucose profiles assessed by continuous glucose monitoring
Blood pressure8 weeksChanges in systolic blood pressure and diastolic blood pressure
Non-esterified fatty acid (NEFA)8 weeksChange in non-essential fatty acid (NEFA)
Plasma gastrointestinal (GI) hormones8 weeksChanges in concentration of fasting and postprandial GI hormones in plasma (ghrelin, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, peptide YY) following a standard breakfast.
Plasma cortisol8 weeksChanges in concentration of cortisol in hourly plasma samples assessed from 6am to 12pm.
Plasma Melatonin8 weeksChanges in dim light melatonin onset (DLMO) assessed from 5pm to 3am
Adipose tissue transcriptome8 weeksA subset will be measured for the change in the adipose tissue transcriptome in 6-hourly samples by RNA-sequencing. The data analysis including but not limited to the changes in numbers of genes oscillated in a diurnal manner, and pathway analysis.
Evening glycaemia8 weeksAn ancillary study will be performed to measure the changes in the concentration of plasma glucose, insulin and GI hormones (ghrelin, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, peptide YY) following a standard evening meal.

Other

MeasureTime frameDescription
Metagenomics and metabolomics8 weeksChanges in metagenome and metabolome in a subset of participants will be assessed in faeces by shotgun metagenomics sequencing and metabolites analysis. The data analysis including but not limited to the function and composition of the gut microbiota, and faecal bile acids.
Plasma proteome8 weeksPlasma proteome will be assessed by mass-spectrometry driven analysis. The data analysis including but not limited to the changes in numbers of proteins oscillated in a diurnal manner, and pathway analysis.
Resting metabolic rate8 weeksA subset of participants will be examined for the changes in resting metabolic rate and respiratory quotient.
Hair follicle clock gene expression8 weeksChanges in the circadian pattern of clock gene expression in hair follicles.

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026